Skip to content

A study of the efficacy of transcranial direct current stimulation in patients with post-stroke cognitive impairment

A study of the efficacy of transcranial direct current stimulation in patients with post-stroke cognitive impairment

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082066
Enrollment
Unknown
Registered
2024-03-20
Start date
2023-06-25
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

experimental group:high- definition transcranial direct current stimulation
control group:Sham stimulation

Sponsors

The Second Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for patients with PSCI in the 2021 Expert Consensus on the Management of Cognitive Impairment after Stroke; (2) Age 30-85 years; (3) Patients with cognitive dysfunction by the screening version of the Brief Intellectual Status Examination Scale and caused by stroke; (4) The patients were in a clear and stable condition, and could cooperate with the relevant examination and treatment and assessment; (5) Voluntary participation and signing of informed consent.

Exclusion criteria

Exclusion criteria: (1) Those with cognitive dysfunction from other causes prior to the onset of stroke; (2) Those who cannot cooperate with cognitive function tests due to dysarthria, blindness, deafness, etc; (3) Patients who exclude other possible causes of cognitive impairment other than stroke; (4) Those who have serious medical system diseases, such as heart failure, renal insufficiency, serious bleeding disorders, malignant tumours, etc.; Inability to cooperate with related treatments and examinations, etc., such as those wearing pacemakers, intracranial metal implants, magnetic tablets, cranial cavities or cracks and those who cannot tolerate adverse reactions.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment Scale;Event-related Potential Measurement (P300);

Secondary

MeasureTime frame
Mini-mental State Examination;

Countries

China

Contacts

Public ContactZhu Wenxin

The Second Affiliated Hospital of Nanjing Medical University

284276964@qq.com+86 158 5696 8658

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026